Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -10 of 100 Show results per page	View Search Criteria \| Help With Results


1.		Chemotherapy for Patients With Non-Small Cell Lung Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase IV				Treatment				Closed				18 and over				Pharmaceutical / Industry				10720 H3E-MC-JMIC, NCT00380718

Last Modified: 6/12/2007 First Published: 5/1/2000


2.		Phase III Randomized Study of Cisplatin With or Without LY231514 in Patients With Malignant Pleural Mesothelioma (Summary Last Modified 02/2001)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Completed				18 and over				NCI, Pharmaceutical / Industry				MSKCC-99085 CWRU-LILY-1599, LILLY-H3E-MC-JMCH(a), NCI-G00-1767, NCT00005636

Last Modified: 4/20/2007 First Published: 11/1/2002


3.		Phase III Randomized Study of Gemcitabine With or Without Pemetrexed Disodium in Patients With Stage II, III, or IV Unresectable Pancreatic Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and over				NCI, Pharmaceutical / Industry				CWRU-010224M NCI-G02-2125, LILLY-H3E-MC-JMES, LILLY-LILY-1201, NCT00049426


4.		A Comparison of Two Doses of Pemetrexed in Patients Who Have Lung Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Completed				18 and over				Pharmaceutical / Industry				8433 H3E-MC-JMGX, NCT00078260


5.		A Randomized Phase 3 Trial of Pemetrexed and Cisplatin Versus Gemcitabine and Cisplatin in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Completed				18 and over				Pharmaceutical / Industry				2938 H3E-MC-JMDB, NCT00087711


6.		Pemetrexed and Best Supportive Care Versus Placebo and Best Supportive Care in Non-Small Cell Lung Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and over				Pharmaceutical / Industry				5122 H3E-MC-JMEN, NCT00102804


7.		Chemotherapy for Patients With Non-Small Cell Lung Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and over				Pharmaceutical / Industry				10717 H3E-MC-JMID, NCT00391274


8.		Efficacy Study Comparing ZD6474 in Combination With Pemetrexed and Pemetrexed Alone in 2nd Line NSCLC Patients

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and over				Pharmaceutical / Industry				D4200C00036 EUDRACT No. 2006-003695-35, NCT00418886

Last Modified: 3/3/2008 First Published: 4/23/2003


9.		Phase I/II Study of Gemcitabine and Pemetrexed Disodium in Patients With Unresectable or Metastatic Biliary Tract or Gallbladder Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Completed				18 and over				NCI				NCCTG-N9943 N9943, NCT00059865


10.		Pemetrexed and Gemcitabine in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Completed				18 and over				Pharmaceutical / Industry				7221 H3E-US-JMGC, NCT00071136

Select All on One Page


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute